Items where Author is "Merat, S."

(2020) SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Clinical Infectious Diseases. pp. 2206-2212. ISSN 1058-4838

(2020) The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment. Journal of Gastroenterology and Hepatology. pp. 1590-1594. ISSN 0815-9319

(2019) Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. pp. 672-683. ISSN 0140-6736

(2019) The combination of sofosbuvir and daclatasvir is well tolerated and extremely effective in treating patients with hepatitis C with severe renal impairment including hemodialysis patinets. Journal of Hepatology. E233-E233. ISSN 0168-8278

(2018) SD1000: 96.4 SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. Journal of Viral Hepatitis. pp. 198-199. ISSN 1352-0504

(2016) Emerging Epidemic of Inflammatory Bowel Disease in a Middle Income Country: A Nation-wide Study from Iran. Archives of Iranian Medicine. pp. 2-15. ISSN 1029-2977

(2016) Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepatitis Monthly. ISSN 1735-143X

(2015) Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial. European Journal of Preventive Cardiology. pp. 1609-1617. ISSN 2047-4873